United States Patent 12,485,120 (US 12,485,120): Scope, Claim Construction Hooks, and US Tenosynovial Giant Cell Tumor Patent Landscape
US Patent 12,485,120 is directed to methods of treating tenosynovial giant cell tumor (TGCT) by administering a pharmaceutical composition containing a specific compound (as recited by the “compound represented by” drawing/structure in the claims) on a twice-weekly schedule, with response and biomarker/time-to-response language locked to outcomes assessed after at least 1 month. Independent claim scope is largely method-based (not compound per se), but it is still constrained by the compound identity, dose ranges (claims 4 and 5), and clinical end points (imaging per CT/MRI/RECIST; range of motion; macrophage infiltration and circulating inflammatory chemokines/cytokines).
Because the method claims include outcome qualifiers, the practical infringement and patent value hinge on: (1) whether the accused regimen is a twice-weekly administration of the claimed compound within the recited dose windows, and (2) whether the regimen is used such that the patient is expected to show the specified clinical/biologic improvements after ≥1 month.
What does US 12,485,120 claim cover for treating tenosynovial giant cell tumor?
Featured snippet answer: US 12,485,120 claims twice-weekly dosing of a defined compound to treat TGCT, with efficacy/endpoints measured after 1 month or more, including imaging response (CT/MRI/RECIST), improved range of motion, and/or reduced macrophage infiltration and/or reduced circulating inflammatory chemokines/cytokines.
Independent claim 1: what is actually required
Claim 1 requires, in combination:
- Patient population: “a patient in need” of treatment for tenosynovial giant cell tumor.
- Therapy type: a method of treating TGCT.
- Drug content: administering a pharmaceutical composition with a therapeutically effective amount of a compound represented by the specified chemical representation.
- Time-to-outcome condition: “after 1 month or more of administration,” the patient has one or more specified improvements:
- (i) improved tumor response measured by CT, MRI and/or RECIST; and/or
- (ii) improved range of motion; and/or
- (iii) reduced macrophage infiltration in the affected joint and/or reduced circulating chemokine/cytokines associated with inflammation, compared to pre-administration levels.
This structure is an “indication + regimen + outcome” claim. Outcome language can become a claim construction battleground: it may be interpreted as (a) a limitation that must be satisfied by the treated patient, and/or (b) a description of the therapy’s expected results used to define the method.
Claims 2 and 3: tumor sub-type narrowing
- Claim 2: tumor is benign.
- Claim 3: TGCT is diffuse-type.
These dependent claims narrow the treated population and can matter if competing regimens target different TGCT phenotypes (localized vs diffuse).
Claims 4 and 5: dose window + schedule
- Claim 4: therapeutically effective amount is ~2 mg to ~60 mg, composition administered twice weekly.
- Claim 5: therapeutically effective amount is ~5 mg to ~30 mg, composition administered twice weekly.
These create explicit dose-range infringement fences. If an accused product is outside both windows (or if mapping dose units differs due to formulation/concentration), the claims may not read cleanly.
Claims 6 to 9: duration
- Twice weekly for ~3 months (claim 6)
- Twice weekly for ~6 months (claim 7)
- Twice weekly for ~1 year (claim 8)
- Twice weekly for ~2 years (claim 9)
These dependents can be important for launch timing analyses. If a competitor uses a shorter early stopping duration, or a different treatment epoch, they may attempt to design around these narrower durations, though claim 1 does not require a specific duration beyond “after 1 month or more.”
How do claims 10–19 broaden or restate scope for US 12,485,120?
Claims 10–19 present parallel method formats anchored to a fixed 30 mg dose:
Claims 10 and 17: 30 mg fixed regimen
- Claim 10: administering a pharmaceutical composition comprising 30 mg of the compound, twice weekly, with post-≥1 month improvements (imaging, range of motion, macrophage infiltration and/or cytokines/chemokines).
- Claim 17: method administering a pharmaceutical composition comprising 30 mg of the compound (twice weekly implied by the claim’s phrasing), similarly tethered to post-≥1 month outcomes.
Claims 11–12 and 18–19: phenotype narrowing
- Claim 11 / 18: tumor is benign.
- Claim 12 / 19: diffuse-type TGCT.
Claims 13–16: treatment durations for the 30 mg regimen
- ~3 months (13)
- ~6 months (14)
- ~1 year (15)
- ~2 years (16)
What are the key claim-scope “hooks” for infringement risk under US 12,485,120?
US 12,485,120 contains three high-leverage claim features that typically drive enforcement and design-around strategies.
1) The compound identity constraint
All claims require a compound “represented by” a particular structure. Any non-identical chemical entity, even with the same target, is not within scope unless the “represented by” language is interpreted broadly enough to encompass structurally equivalent compounds.
2) Twice-weekly regimen constraint
Independent claim 1 does not expressly say “twice weekly” in the text of claim 1 as you provided it, but it is present through dependent claims and reflected in the overall method set; claims 4–9 and 10–16 are explicit. Practically, this is a regimen-limiting element. If the accused regimen is weekly, every-other-week, or continuous daily dosing, read-across is reduced.
3) The post-≥1 month efficacy/biomarker condition
Claim 1 requires that “after 1 month or more” the patient has one or more of the listed improvements. That can raise questions about how courts treat “has” clauses:
- If construed as a result limitation, enforcement may require evidence the accused method yields the specified improvement(s).
- If construed as a method definition based on therapy’s intended effect, enforcement may rely on clinical data showing that the therapy produces the improvements within that timeframe.
Biomarker language includes both:
- local effect: macrophage infiltration in the affected joint, and
- systemic effect: circulating chemokine/cytokines.
That combination can complicate generic or biosimilar-style substitution arguments because a competitor may attempt to show that its dosing schedule leads to different biomarker profiles, even if clinical imaging improves.
What is the likely patent estate breadth beyond US 12,485,120?
Your prompt provides the claims of US 12,485,120 but not the drug name, compound, application family, priority data, or related patents. Without those identifiers, it is not possible to produce a complete and accurate US/WO/EU patent estate map tied to this exact compound and indication.
That said, based on the internal structure of the claims, the landscape risk usually clusters into these buckets in TGCT programs:
- Method-of-use patents: similar “treat TGCT” claims with imaging/RECIST/time-to-response.
- Dose/regimen patents: twice-weekly schedules; specific mg ranges; duration windows.
- Biomarker patents: macrophage infiltration and inflammatory chemokines/cytokines as efficacy correlates.
- Formulation/administration patents: stable compositions enabling the specific dose schedule (not shown in your claim excerpt).
- Combination therapy patents: if any exist, they would typically appear as additional “administering together” claim types.
A business implication: even if US 12,485,120 is a method claim, competitors often face parallel restrictions via other method/regimen patents in the same family or continuation filings.
When does US 12,485,120 lose exclusivity based on typical US patent term rules?
US patent term in the US generally runs 20 years from the earliest non-provisional effective filing date, with adjustments (e.g., PTA). However, determining the actual expiration for US 12,485,120 requires the patent’s priority/filing history and any terminal disclaimer and Patent Term Adjustment figures, none of which are included in your prompt.
Accordingly, a precise exclusivity timeline cannot be stated from the claim text alone.
What generic entry risks exist for therapies that treat TGCT using similar twice-weekly dosing?
Design-around pathways
For method claims like these, generic or alternative entrants typically try one or more of:
- Switch dosing frequency (avoid twice-weekly) to target dependent-claim vulnerabilities and weaken read-across to the independent claim’s regimen logic.
- Use different dose outside 2–60 mg and 5–30 mg windows, if those windows map to fixed unit doses and the regimen is still twice weekly.
- Change clinical/biomarker expectations (hardest to do ethically/medically).
- Treat different TGCT subsets if feasible (claims 2/3 and 11/12 and 18/19 can matter in segment-specific label or off-label marketing).
Paragraph IV and litigation profile
Whether US 12,485,120 could be asserted in a Paragraph IV certification depends on whether it is listed in the relevant FDA Orange Book for the specific drug/strength and whether the ANDA label carve-ins would avoid the claimed conditions. Orange Book status is not provided in your prompt.
What formulations are protected by US 12,485,120?
The claims refer to a “pharmaceutical composition” but do not, in your excerpt, recite formulation components (excipients, salt forms, particle size, release profile, etc.). The “composition” appears mainly as a delivery vehicle for the claimed compound and dose.
So the formulation scope in US 12,485,120 is typically:
- limited to the presence of the claimed compound at a therapeutically effective amount (and in dependent claims, within specific mg ranges and a twice-weekly schedule),
- not necessarily limited by formulation details (since none are recited here).
From an engineering standpoint, the claims are more likely to hit what is administered and how often, rather than the precise manufacturing attributes, unless separate formulation patents exist.
How strong is the patent estate for TGCT methods using macrophage/cytokine biomarkers?
Strength indicators from the claim language:
- Broad clinical endpoints: imaging modalities (CT/MRI) and RECIST provide multiple ways to satisfy “improved tumor response.”
- Multiple efficacy modalities: range-of-motion and biomarker reduction provide alternative endpoints. A method can potentially satisfy the claim even if one endpoint is disputed.
- Time tether: “after 1 month or more” is a specific temporal anchor that aligns with clinical trial observation schedules.
Key vulnerability for an accused infringer:
- If the compound is not identical to the “represented by” chemical entity, the claim does not apply.
- If regimen frequency and dose do not match dependent windows and if independent claim interpretation requires regimen constraints, infringement arguments weaken.
What patent litigation affects commercialization of TGCT therapies?
No litigation identifiers, asserted patents, court dockets, or settlement details were supplied with US 12,485,120. The claim text alone does not establish enforcement history.
As a result, a litigation-anchored analysis cannot be produced accurately.
Key Takeaways
- US 12,485,120 is a TGCT method-of-treatment patent that ties therapy to a defined compound, twice-weekly dosing (explicit in multiple dependents), and post-≥1 month efficacy outcomes assessed by CT/MRI/RECIST, range of motion, and/or macrophage infiltration and inflammatory chemokine/cytokine reductions.
- Dependent claims narrow scope by benign vs diffuse-type TGCT and by dose windows (~2–60 mg; ~5–30 mg) and fixed 30 mg dosing, plus specific treatment durations (3 months through 2 years).
- The highest practical design-around levers are: compound identity, dosing frequency, and dose mapping; biomarker outcome language increases the evidentiary burden for enforcement but also broadens what counts as “improvement.”
FAQs
- Can a different dosing frequency avoid infringement of US 12,485,120?
- How do RECIST/CT/MRI outcome requirements affect enforcement under result-limited method claims?
- Do the macrophage infiltration and circulating cytokine/chemokine elements create separate infringement pathways?
- How do the fixed-dose (30 mg) dependents change generic “skinny label” strategies?
- What happens if a patient shows imaging improvement but not range-of-motion improvement under the claim language?
References
- United States Patent 12,485,120, “Method of treating tenosynovial giant cell tumor,” claims provided in prompt.
